Combination Pricing Solution As Elusive As Ever
Executive Summary
The pricing of combination therapies, particularly in oncology, remains a headache for payers and companies.
You may also be interested in...
Better Data Tracking Could Hold Key To Indication-Based Pricing Progress
Indication-based pricing could become a reality with better infrastructure to track utilization data.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.